✦ LIBER ✦

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Scribed by Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang Howson-Jan; Kevin Imrie; Robert Myers; Grenfell Adams; Keyue Ding; Nancy Paul; Lois Shepherd; Jose Iglesias; Ralph Meyer

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 91 KB
Volume: 101
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20587

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati